https://pharminent.com/oncology/oncology-intelligence-digest-june-5-2026/ 2026-06-06T17:22:30Z Pharminent en Oncology Intelligence Digest • June 5, 2026 2026-06-06T17:22:27Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-june-5-2026/ 2026-06-05T19:25:46Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • June 5, 2026 2026-06-05T19:25:42Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-5-2026/ 2026-06-05T18:51:11Z Pharminent en Strategic News Watch • June 5, 2026 2026-06-05T18:46:10Z Blog https://pharminent.com/lilly-and-novo-face-off-at-ada-2026-as-others-seek-to-compete-in-obesity/ 2026-06-05T16:23:46Z Pharminent en Lilly and Novo face off at ADA 2026 as others seek to compete in obesity 2026-06-05T13:36:00Z Blog https://pharminent.com/the-next-fda-commissioner-must-be-a-champion-for-gene-therapies/ 2026-06-05T16:23:55Z Pharminent en The next FDA commissioner must be a champion for gene therapies 2026-06-05T13:00:00Z Blog https://pharminent.com/medicare-advantage-in-2026-enrollment-update-and-key-trends/ 2026-06-05T16:23:52Z Pharminent en Medicare Advantage in 2026: Enrollment Update and Key Trends 2026-06-05T13:00:00Z Blog https://pharminent.com/otsuka-energizes-iga-neuropathy-space-with-new-phase-3-voyxact-data/ 2026-06-05T16:23:58Z Pharminent en Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data 2026-06-05T12:00:44Z Blog https://pharminent.com/stakeholders-want-makarys-voucher-program-paused-call-for-fda-independence/ 2026-06-05T16:24:02Z Pharminent en Stakeholders want Makary's voucher program paused, call for FDA independence 2026-06-05T11:25:30Z Blog https://pharminent.com/pharma-is-betting-big-on-pd-1-vegf-bispecifics-but-are-companies-chasing-the-wrong-target/ 2026-06-05T16:24:03Z Pharminent en Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? 2026-06-05T11:00:00Z Blog https://pharminent.com/biogens-salanersen-gains-fda-breakthrough-therapy-designation-for-sma/ 2026-06-05T16:24:06Z Pharminent en Biogen's salanersen gains FDA breakthrough therapy designation for SMA 2026-06-05T09:21:56Z Blog https://pharminent.com/pfizer-signs-licence-agreement-with-chai-for-ai-drug-discovery-2/ 2026-06-05T16:24:09Z Pharminent en Pfizer signs licence agreement with Chai for AI drug discovery 2026-06-05T09:17:54Z Blog https://pharminent.com/81492-2/ 2026-06-04T22:10:20Z Pharminent en 2026-06-04T22:10:13Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-june-4-2026/ 2026-06-04T22:05:11Z Pharminent en Rare Disease & Gene Therapy Digest • June 4, 2026 2026-06-04T22:05:06Z Blog https://pharminent.com/boan-biotech-submits-bla-to-fda-for-two-denosumab-biosimilars/ 2026-06-05T16:32:32Z Pharminent en Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars 2026-06-04T20:01:18Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-4-2026/ 2026-06-04T17:02:29Z Pharminent en Strategic News Watch • June 4, 2026 2026-06-04T17:02:25Z Blog https://pharminent.com/scotus-backs-generic-firm-hikma-in-skinny-label-dispute/ 2026-06-05T16:32:06Z Pharminent en SCOTUS backs generic firm Hikma in skinny label dispute 2026-06-04T16:57:34Z Blog https://pharminent.com/adc-therapeutics-slumps-on-cancer-drug-safety-scare/ 2026-06-04T17:57:16Z Pharminent en ADC Therapeutics slumps on cancer drug safety scare 2026-06-04T14:30:49Z Blog https://pharminent.com/peptide-biotech-parabilis-targets-up-to-476m-ipo/ 2026-06-04T17:57:22Z Pharminent en Peptide biotech Parabilis targets up to $476M IPO 2026-06-04T13:48:45Z Blog https://pharminent.com/regeneron-deepens-relationship-with-cytomx-adding-up-to-2b-and-eight-targets/ 2026-06-04T17:57:25Z Pharminent en Regeneron deepens relationship with CytomX, adding up to $2B and eight targets 2026-06-04T11:11:41Z Blog https://pharminent.com/alnylam-hops-on-ai-train-with-up-to-2b-inceptive-partnership/ 2026-06-04T17:57:27Z Pharminent en Alnylam hops on AI train with up to $2B Inceptive partnership 2026-06-04T10:32:05Z Blog https://pharminent.com/johnson-johnson-reports-phase-2-data-showing-nipocalimab-reduced-sle-disease-activity/ 2026-06-04T17:57:27Z Pharminent en Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity 2026-06-04T10:10:38Z Blog https://pharminent.com/eli-lilly-continues-genetic-medicine-push-with-1-9bn-ascidian-partnership/ 2026-06-04T17:57:29Z Pharminent en Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership 2026-06-04T09:44:36Z Blog https://pharminent.com/cellares-and-tscan-to-assess-automated-manufacturing-of-tsc-101-therapy-2/ 2026-06-04T17:57:31Z Pharminent en Cellares and TScan to assess automated manufacturing of TSC-101 therapy 2026-06-04T09:28:43Z Blog https://pharminent.com/a-spanish-biotech-banks-87m-to-make-differentiated-adcs/ 2026-06-04T17:57:34Z Pharminent en A Spanish biotech banks $87M to make differentiated ADCs 2026-06-04T07:00:00Z Blog